Our neoteric approach

At Cellworks, we are changing the way therapeutics are designed. We have a deep understanding of the holistic disease physiology and not restricted to selected cellular processes and pathways. The therapeutics product engine improves clinical outcomes and shortens time to clinical proof of concept. This approach uses proprietary simulation technology which emulates disease biology and uses an engineering infrastructure. Modeling of biological relationships using mathematics and best practices from semiconductor automation engineering makes simulation of millions of in vivo studies in days possible. Simulation provides the needed transparency for automated analysis of the study outcomes and identify opportunities of synergism, synthetic lethality and overcoming resistance mechanisms.

This approach is agnostic to specific collection of pathways or targets. The Cellworks simulation model is a comprehensive representation of disease biology integrating signaling and metabolic networks across all phenotypes enabling coming up with a treatment which is right for the target population.

The factors contributing to improved accuracy of predictions of Cellworks products is due to its validated simulation technology and strategy based on novel biological mechanisms implemented using clinically validated drugs.

Cellworks has a pipeline of therapeutic products designed using the product engine. These have been validated in various non-clinical models. Also the predictive simulation technology has been extensively validated against prospective and retrospective in vitro, ex vivo, in vivo and clinical outcomes.

The strategy for products differentiation is through designing novel first-in-class biological mechanisms using clinically validated molecularly targeted drug agent(s) in sub-therapeutic combinations. The clinically validated molecularly targeted drug agents can be approved or failed due to lack of efficacy or in clinical development.

The conventional drug development cycle is extremely long and failures are the main reason for inflated costs. The more the number of failures later in the development stage; the higher is the amortized cost of developing a drug. The high failure rate mandates multiple shots at the goal approach and consequentially large development costs.

Cellworks therapeutic products with novel biological mechanisms use clinically validated drug agents to reduce the novel chemistry associated failures. Improved clinical outcomes and accuracy of predictions reduces the need for multiple shots at the goal. In addition simulation based therapeutic design reduces the number of non-clinical studies to mainly validations. Implicitly all these factors reduce cost and length of time to clinical proof of principle.

Large number of drug agents across industry is shelved due to failures for lack of efficacy. Plus increasing number of approved drugs are going off patent. Clinical safety and pharmacokinetic data is available for all these drug agents.

Recycling or repurposing of both these classes of drug agents to create novel biological mechanisms for same or new therapeutic indications provides new product opportunities.